Explore /
Poster
/ Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

Authors

Emmanuel S. Antonarakis

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Emmanuel S. Antonarakis , Russell Madison , Jeremy Snider , Tamara Snow , Ethan Sokol , Jon Chung , Margaret Elizabeth McCusker , Gaurav Singal , Brian Michael Alexander , Emily Castellanos , Jeffrey Venstrom , Alexa Betzig Schrock , Jeffrey S. Ross

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5527)

DOI

10.1200/JCO.2020.38.15_suppl.5527

Abstract #

5527

Poster Bd #

108

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

$Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).$